Ascendis Pharma A/S (NASDAQ:ASND) Sets New 1-Year High - Here's What Happened

Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) hit a new 52-week high on Friday . The stock traded as high as $157.40 and last traded at $155.51, with a volume of 179633 shares. The stock had previously closed at $153.14.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Wedbush restated an "outperform" rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. The Goldman Sachs Group lifted their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Cantor Fitzgerald raised their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. Finally, Oppenheimer reduced their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $202.36.

Ascendis Pharma A/S Price Performance

The business's 50-day moving average is $136.35 and its 200 day moving average is $134.01. The firm has a market capitalization of $9.14 billion, a P/E ratio of -21.16 and a beta of 0.64.

Remove Ads

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. Analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently made changes to their positions in ASND. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at $28,000. Wilmington Savings Fund Society FSB bought a new position in shares of Ascendis Pharma A/S during the third quarter worth about $30,000. Jones Financial Companies Lllp lifted its stake in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 197 shares during the period. Blue Trust Inc. lifted its stake in shares of Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 328 shares during the period. Finally, Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at $60,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.